Medication Access In A Shortage
Increasing access to medication that helps people drink less or quit has been at the heart of Oar’s mission from day one. Since then, we’ve helped more than 30,000 people get access to safe, effective medication privately and conveniently. However, the last three months have been the most challenging time in our history to meet that simple goal. A market-wide
shortage of
naltrexone tablets developed in November and continues today, caused by a shortage of the medication’s active pharmaceutical ingredient. Oar has been able to maintain medication in hand for all of our members during the shortage by working closely with our partner pharmacy, pharmaceutical distributors and the manufacturers of generic naltrexone. We are proud that our track record as a large purchaser of naltrexone and industry relationships have allowed us to maintain medication in hand for members during times when patients have been unable to fill naltrexone prescriptions at prominent digital and retail pharmacies. We remain ready to accept new members at
www.oarhealth.com.
However, the shortage has been difficult for Oar and our members. We have had to limit the number of new members that we accept, ship orders in 30 tablet quantities instead of the larger quantities that many members prefer, and change the manufacturer that we source from. While generic naltrexone from any FDA-approved manufacturer must have
bioequivalence, the changes in tablet color and shape from manufacturer to manufacturer have been confusing and disruptive for some members.
We are doing everything possible to re-establish a reliable and sustainable supply of naltrexone that meets the current and projected needs of our members. Based on conversations with numerous industry participants, we are hopeful that supply increases substantially within the next few months.
But the naltrexone shortage is not an isolated issue. Generic drug shortages are at a
10 year high, extending beyond alcohol use disorder to other critical therapeutic areas such as chemotherapy, antibiotics, and ADHD medications. The generic drug supply chain is
too brittle. Restoring its resiliency will likely require
government action. If you are concerned about the supply of naltrexone and other critical generic medications, we encourage you to share your concerns with your representatives in Washington, D.C.